Cancer news

Latest news, press releases and blog posts from Cancer Research UK.

Brain Tumour Primary

Zika virus shrinks brain tumours in lab tests

The Zika virus can target and kill a particular type of brain tumour cell in the lab.

‘Practice changing’ study defines standard of care for elderly glioblastoma patients

Using chemotherapy alongside radiotherapy can extend the lives of elderly patients with glioblastoma, according to a Canadian study.

Gene linked to brain defect could point to a new brain tumour drug target

Research into a rare genetic disease could help scientists understand a type of brain tumour.

Brain tumour characteristics could help predict survival in people over 70

Characteristics like seizures, location of the tumour, and pressure in the brain, give insight into survival and treatment options for patients over 70.

Giving chemotherapy after radiotherapy improves survival for patients with rare brain tumour

Giving chemotherapy after radiotherapy delays further growth of a rare type of brain tumour, increasing the number of patients alive at five years.

International trial for children’s brain tumours launches in the UK

Cancer Research UK Kids & Teens launches the UK arm of a large international clinical trial* for a type of children’s brain tumour, called ependymoma.

Scientists discover new way to tackle challenging children’s brain tumours

Scientists have discovered why a curable type of children’s brain tumour is so responsive to chemotherapy.

Scientists discover how to better map brain tumours

Scientists have discovered a protein that helps map the edge of brain tumours more clearly so they show up on magnetic resonance imaging (MRI) scans.

Large analysis supports possible link between obesity and rare brain tumour

A very rare type of brain tumour may be slightly more common among people who are overweight or obese.

Tetanus shot boosts response to experimental brain tumour treatment

An immune-boosting tetanus injection improved the effectiveness of an experimental brain tumour immunotherapy in a US study of 12 patients.